Initial Director's Interest Notice - Michael Sistenich
Released
Released
Announcement PDF
Rule 3.19A.1
Appendix 3X
Initial Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents
given to ASX becomes ASX's property and may be made public.
Introduced 30/9/2001.
We (the entity) give ASX the following information under listing rule 3.19.A.1 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Appendix 3X
Initial Director's Interest Notice
Name of entity RESONANCE HEALTH LIMITED
ABN 96 006 762 492
Name of director Michael Sistenich
Date of appointment 28 April 2026
Part 1 - Director's relevant interests in securities of which the director is the registered
holder
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a
director" should be disclosed in this part.
Number & class of securities
NIL
Part 2 - Director's relevant interests in securities of which the director is not the
registered holder
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Name of holder & nature of
interest
Number & class of Securities
Note: Provide details of the circumstances
giving rise to the relevant interest.
NIL
Not applicable
0 - ORDINARY FULLY PAID SHARES
0 - ORDINARY FULLY PAID SHARES
Part 3 - Director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a
director" should be disclosed in this part.
Detail of contract NIL
Nature of interest NIL
Name of registered holder (if
issued securities)
NIL
+ See chapter 19 for defined terms.
11/03/2002 Appendix 3X Page 1
Appendix 3X
Initial Director's Interest Notice
No. and class of securities to
which interest relates
NIL
+ See chapter 19 for defined terms.
Appendix 3X Page 2 11/03/2002
Share your feedback
Discover